JP2024075520A5 - - Google Patents

Info

Publication number
JP2024075520A5
JP2024075520A5 JP2024025650A JP2024025650A JP2024075520A5 JP 2024075520 A5 JP2024075520 A5 JP 2024075520A5 JP 2024025650 A JP2024025650 A JP 2024025650A JP 2024025650 A JP2024025650 A JP 2024025650A JP 2024075520 A5 JP2024075520 A5 JP 2024075520A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
human
composition according
administration
cardiomyopathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024025650A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024075520A (ja
Filing date
Publication date
Priority claimed from JP2020550147A external-priority patent/JP7811087B2/ja
Application filed filed Critical
Publication of JP2024075520A publication Critical patent/JP2024075520A/ja
Publication of JP2024075520A5 publication Critical patent/JP2024075520A5/ja
Pending legal-status Critical Current

Links

JP2024025650A 2018-03-23 2024-02-22 Ag10を使用するttrアミロイドーシスの治療方法 Pending JP2024075520A (ja)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201862647411P 2018-03-23 2018-03-23
US62/647,411 2018-03-23
US201862765096P 2018-08-17 2018-08-17
US62/765,096 2018-08-17
US201862731629P 2018-09-14 2018-09-14
US62/731,629 2018-09-14
US201862758235P 2018-11-09 2018-11-09
US62/758,235 2018-11-09
US201962810651P 2019-02-26 2019-02-26
US62/810,651 2019-02-26
JP2020550147A JP7811087B2 (ja) 2018-03-23 2019-03-22 Ag10を使用するttrアミロイドーシスの治療方法
PCT/US2019/023555 WO2019183463A1 (en) 2018-03-23 2019-03-22 Methods of treating ttr amyloidosis using ag10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020550147A Division JP7811087B2 (ja) 2018-03-23 2019-03-22 Ag10を使用するttrアミロイドーシスの治療方法

Publications (2)

Publication Number Publication Date
JP2024075520A JP2024075520A (ja) 2024-06-03
JP2024075520A5 true JP2024075520A5 (enExample) 2026-03-16

Family

ID=67984563

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020550147A Active JP7811087B2 (ja) 2018-03-23 2019-03-22 Ag10を使用するttrアミロイドーシスの治療方法
JP2024025650A Pending JP2024075520A (ja) 2018-03-23 2024-02-22 Ag10を使用するttrアミロイドーシスの治療方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020550147A Active JP7811087B2 (ja) 2018-03-23 2019-03-22 Ag10を使用するttrアミロイドーシスの治療方法

Country Status (15)

Country Link
US (3) US11058668B2 (enExample)
EP (1) EP3768841A4 (enExample)
JP (2) JP7811087B2 (enExample)
KR (1) KR102924979B1 (enExample)
CN (1) CN112218632A (enExample)
AU (2) AU2019239291A1 (enExample)
CA (1) CA3094711A1 (enExample)
IL (1) IL277379A (enExample)
MA (1) MA52137A (enExample)
MX (1) MX2020009844A (enExample)
MY (1) MY208459A (enExample)
SG (1) SG11202009073WA (enExample)
TW (3) TWI817999B (enExample)
UA (1) UA130053C2 (enExample)
WO (1) WO2019183463A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116730921A (zh) 2017-02-17 2023-09-12 文涵治疗有限公司 Ag-10的制备方法、其中间体及其盐
MA52137A (fr) * 2018-03-23 2021-01-27 Eidos Therapeutics Inc Méthodes de traitement de l'amylose ttr à l'aide d'ag10
JP7469293B2 (ja) 2018-08-17 2024-04-16 エイドス セラピューティクス,インコーポレイティド Ag10の製剤
US20250027943A1 (en) * 2021-09-07 2025-01-23 Siemens Healthcare Diagnostics Inc. Biomarker compositions and methods of use thereof
WO2023052652A1 (en) * 2021-10-01 2023-04-06 Sandoz Ag Crystalline form of acoramidis hydrochloride
WO2024182635A1 (en) * 2023-03-01 2024-09-06 Eidos Therapeutics, Inc. Potent transthyretin (ttr) stabilization in ttr amyloidosis patients receiving acoramidis
WO2025235883A1 (en) * 2024-05-10 2025-11-13 Eidos Therapeutics, Inc. Acoramidis for use in the treatment of renal dysfunction

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4255329A (en) 1973-10-02 1981-03-10 Syva Company Double receptor fluorescent immunoassay
US4117149A (en) 1975-09-12 1978-09-26 Pfizer Inc. 4-oxo-4h-benzopyrans as animal growth promotants
US4261928A (en) 1977-08-05 1981-04-14 Sterling Drug Inc. 2-Benzoyl-8-(2-chloro-4-methoxyphenoxy)-1-phenyl-1-octanone
US4171365A (en) 1977-08-05 1979-10-16 Sterling Drug Inc. Antiviral aryloxyalkylpyrazoles
US4234725A (en) 1979-10-24 1980-11-18 Sterling Drug Inc. 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-[4-(4-morpholinyl)-1-oxobutyl]-1H-pyrazole
US4232161A (en) 1979-10-24 1980-11-04 Sterling Drug Inc. 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-(2-pyridinyl)-1H-pyrazole
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4668640A (en) 1981-12-11 1987-05-26 Abbott Laboratories Fluorescence polarization immunoassay utilizing substituted carboxyfluoresceins
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
GB2120242A (en) 1982-04-30 1983-11-30 Erba Farmitalia Ergoline derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4764521A (en) 1983-07-18 1988-08-16 Eli Lilly And Company Leukotriene antagonists and a method of use there as
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5315015A (en) 1992-11-10 1994-05-24 Hoffmann-La Roche Inc. Compounds having improved fluorescence in fluorescence polarization immunoassays and immunoassays utilizing same
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
HU224548B1 (hu) 1993-04-07 2005-10-28 Taiho Pharmaceutical Co. Ltd. Tiazolidinszármazékok és ezeket tartalmazó gyógyszerkészítmények, valamint eljárás előállításukra
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
AU722289B2 (en) 1996-10-01 2000-07-27 Aptalis Pharmatech, Inc. Taste-masked microcapsule compositions and methods of manufacture
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
CN1152673C (zh) 1997-10-28 2004-06-09 坂东化学株式会社 皮肤贴附药片及其基片的制造方法
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
NZ519984A (en) 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
JP2005513026A (ja) 2001-11-15 2005-05-12 インサイト サン ディエゴ インコーポレイテッド 高コレステロール血症、異脂肪血症および他の代謝障害;癌、および他の疾患を治療するn−置換複素環
SI1511710T1 (sl) 2002-05-31 2014-04-30 Proteotech, Inc. Spojine, sestavki in postopki za zdravljenje amiloidnih bolezni in sinukleinopatij, kot je Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsova bolezen
WO2004096808A1 (en) 2003-04-28 2004-11-11 De Novo Pharmaceuticals Limited Triazine compounds and their use
JP4880591B2 (ja) 2004-06-04 2012-02-22 テバ ファーマシューティカル インダストリーズ リミティド イルベサルタンを含む医薬組成物
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
WO2006088694A1 (en) 2005-02-14 2006-08-24 Wyeth SUBSTITUTED THIENYL AND FURYL ACYLGUANIDINES AS β-SECRETASE MODULATORS
US20070043097A1 (en) 2005-07-18 2007-02-22 Horizon Therapeutics, Inc. Medicaments containing famotidine and ibuprofen and administration of same
EP2102165A2 (en) 2006-11-24 2009-09-23 AC Immune S.A. N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's
MX2009006756A (es) 2006-12-22 2009-06-30 Novartis Ag Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv.
PT2155717E (pt) 2007-05-11 2012-12-21 Lilly Co Eli 2-[4-(pirazol-4-ilalquil)piperazin-1-il]-3-fenil-pirazinas e -piridinas e 3-[4-(pirazol-4-ilalquil)piperazin-1-il]-2- fenil-piridinas como antagonistas do recetor 5-ht7
NZ581127A (en) 2007-05-25 2012-06-29 Abbott Gmbh & Co Kg Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
JP5243537B2 (ja) 2007-06-06 2013-07-24 トレント ファーマシューティカルズ リミテッド 新規化合物
SG182187A1 (en) 2007-06-08 2012-07-30 Abbott Gmbh & Co Kg 5-heteroaryl substituted indazoles as kinase inhibitors
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
PT2260020E (pt) 2008-03-26 2014-10-28 Novartis Ag Inibidores das desacetilases b baseados no hidroxamato
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
US8048887B2 (en) 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7994171B2 (en) 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
SG10201809460SA (en) * 2008-10-20 2018-11-29 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of transthyretin
US8697685B2 (en) 2008-11-20 2014-04-15 Glaxosmithkline Llc Chemical compounds
EP2488028B1 (en) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
BR112012026255A2 (pt) 2010-04-07 2017-03-14 Vertex Pharma composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas
WO2011140333A1 (en) 2010-05-07 2011-11-10 The Board Of Trustees Of The Leland Stanford Junior University Identification of stabilizers of multimeric proteins
RU2013132650A (ru) 2010-12-16 2015-01-27 Аллерган, Инк. Серные производные в качестве модуляторов хемокиновых рецепторов
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
LT3185957T (lt) 2014-08-29 2022-09-26 Alnylam Pharmaceuticals, Inc. Patisiranas, skirtas naudoti transtiretino amiloidozei gydyti
EA201792592A1 (ru) 2015-06-30 2018-06-29 Джилид Сайэнс, Инк. Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
UA121775C2 (uk) 2015-07-31 2020-07-27 Пфайзер Інк. 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
CN116730921A (zh) * 2017-02-17 2023-09-12 文涵治疗有限公司 Ag-10的制备方法、其中间体及其盐
MA52137A (fr) * 2018-03-23 2021-01-27 Eidos Therapeutics Inc Méthodes de traitement de l'amylose ttr à l'aide d'ag10
JP7469293B2 (ja) 2018-08-17 2024-04-16 エイドス セラピューティクス,インコーポレイティド Ag10の製剤

Similar Documents

Publication Publication Date Title
JP2024075520A5 (enExample)
Grippo et al. A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma
JP7668777B2 (ja) 癌治療
TWI798199B (zh) 癌症治療
BR112020001285A2 (pt) s-enantiômeros de beta-hidroxibutirato e butanodiol e métodos para sua utilização
TW202327597A (zh) 一種ezh2抑制劑用於製備治療t細胞淋巴瘤的藥物的用途
JP2012162581A (ja) 経口治療用化合物の供給系
JP6328146B2 (ja) 神経変性およびその他の疾患の治療用組成物および方法
US12116363B2 (en) Combinations for immune-modulation in cancer treatment
JP2022116304A (ja) 血液がんの治療のためのPPARγアゴニスト
EA032067B1 (ru) Совместное введение стероидов и золедроновой кислоты для профилактики и лечения остеоартрита
JP2007291067A (ja) 医薬組成物
JP2017031209A (ja) アタシセプトなどのTACI−Ig融合タンパク質を用いた自己免疫疾患を治療するための投薬法
JP2012525423A (ja) 抗ヒスタミン剤と鎮咳剤と充血緩和剤とを徐放性製剤中に含む組成物
TW202203934A (zh) 治療涉及全身過度發炎性反應的病症的受體相互作用蛋白激酶抑制劑
BR112021015686A2 (pt) Tratamento de câncer
JP2022058873A5 (enExample)
Oettmeier et al. The procainebase-infusion: 20 years of experience of an alternative use with several therapeutical effects
TW201200139A (en) Oral B12 therapy
CN1646130A (zh) 类风湿性关节炎的治疗
CN1204881C (zh) 烯丙胺衍生物在制备治疗幽门螺杆菌感染和相关疾病的药物方面的用途
BRPI0606805A2 (pt) kit, e, unidade de dosagem
JP4384435B2 (ja) くしゃみ抑制組成物
US20210283096A1 (en) Methods of treating obesity in responder and non-responder populations
NO327358B1 (no) Anvendelse av en kombinasjon for behandling av proliferative sykdommer